ClinicalTrials.gg
RecruitingNCT03506997PERSEUS1Updated Jul 22, 2020

Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

A Phase 2 interventional study of Pembrolizumab in Castration-resistant Prostate Cancer, sponsored by Institute of Cancer Research, United Kingdom. Recruiting at 1 site in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-22.

Sponsored by Institute of Cancer Research, United Kingdom · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 2 months ago, but the record still lists the study as recruiting.
  • Started Nov 2018; still recruiting 7 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing pembrolizumab in Prostatic Neoplasms — 4 open to participants now, 8 under way, none of them phase 3. pembrolizumab · Prostatic Neoplasms.

Planned enrollment
5th of 20
100 · median 41
Started
2018
with 2 others
Phase 2
13 of 20
4 open now
Registered
6th of 20
by date
Lead sponsor
1 of 20
Institute of Cancer Research, United Kingdom

Among the 20 studies testing pembrolizumab in Prostatic Neoplasms, this one is the 5th largest by planned enrollment, is one of 3 that started in 2018, is one of 13 in phase 2, and was the 6th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 20 studies testing pembrolizumab in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing pembrolizumab in Prostatic Neoplasms, or all of them as a file.
02

Study summary

PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is shown in part A.

Read the detailed description

Open-label, single arm, phase II trial initially pursuing a two-stage Simon Minimax design. The null hypothesis Po will be 0.20; the alternative hypothesis Pa will be 0.40 (type 1 error will be 0.05 and type 2 error will be 0.10).

Patients with metastatic CRPC tumours characterised by high mutational load, high microsatellite instability as established, for example, by the Promega MSI 1.2 analysis system, or a DNA repair defect including loss of MMR, identified on archival or fresh tissue biopsy specimens (through a TMG approved sequencing study e.g. the MAESTRO study) who have either exhausted established active anticancer drugs, or preferred not to have established agents, will be offered entry into the PERSEUS1 study.

Part A: Part A is an open-label, single arm, two-stage Simon Minimax design phase II trial.

Stage 1: Patients will continue their LHRH analogue therapy. This cohort will include 24 patients as the first stage of a two-stage Phase II. If more than 5 responses in these first 24 patients are reported then the study will proceed to stage 2. Anti-tumour activity will be assessed (measured by response rates) by PSA, imaging assessments (CT \& bone scans or when indicated whole body MRI) and CTC count measures. Whole Body MRI (WB-MRI) will be performed instead of CT in patients with contraindications to CT contrast), or instead of bone scan in patients with widespread bone disease at baseline thought to be non-evaluable by PCWG criteria due to inability to reliably identify two new lesions.

Stage 2: This will enrol a further 21 patients to a total of 45 patients. Ineffectiveness will be concluded if ≤5 and ≤13 responses are seen in the stage 1 and stage 2 respectively and the null hypothesis will be rejected (i.e. further research would be warranted) if >13 responses are reported from the first 45 patients.

With this Simon Minimax design the probability of early termination of this trial when the true response probability (P0) is \<0.20 is 0.66.

Part B: Biomarker enrichment stage: If the null hypothesis is rejected (and with Sponsor approval and confirmation of sufficient funding) the study will continue with stratified recruitment into biomarker defined cohorts in order to increase the precision with which the response rate can be estimated within mCRPC molecular subgroups of interest. It is anticipated that approximately 55 patients will be included in Part B, which will make a total of 100 mCRPC patients in part A and B together, including ≥9 patients for each of:

A) MMR defective mCRPC; B) High mutational load mCRPC without MMR defects; C) mCRPC with deleterious homologous recombination (HR) DNA repair aberrations (BRCA2, ATM, BRCA1, PALB2, others); D) mCRPC with deleterious nucleotide excision repair (NER) aberrations; E) mCRPC with deleterious base excision repair (BER) aberrations; F) mCRPC with deleterious aberrations in non-homologous end-joining (NHEJ).

Eligibility for more than one cohort is anticipated to be uncommon; where this occurs "allocation" to a cohort will be determined in discussion with the CI based on initial sequencing results and with priority given to driver (rather than sub-clonal) mutations. Patients recruited in Part A will be retrospectively "allocated" to a cohort on the basis of their initial sequencing data (reported prior to trial entry) prior to any response assessments, for the purposes of analysis. Within each biomarker subgroup (A-F) this will allow us to reject the probability of a >30% response rate if we see no responses in 9-patients, with a 5% false negative risk (Gehan design). If ≥1 responses are seen in 9 patients in a subtype, recruitment will continue to that subtype with a further 20-25 patients such that the final estimate of the response rate has a standard error of 10%. Response rates with confidence intervals will be reported for each subtype.

In the absence of any safety concerns from the IDMC, recruitment will continue seamlessly from Part A stage 1 to Part A stage 2 and from Part A stage 2 to the Part B biomarker enrichment cohorts. It is possible that at the time of the Part A stage 1 and 2 overall analysis (based on 45 patients), the graduation of some of the more common subgroups to the enrichment phase will be known (e.g. if more than 1 response from 9 patients recruited to a biomarker subgroup that cohort would continue to at least 20 patients). Conversely, if no successes have been seen in 9 patients of a particular subtype, recruitment to that subtype would not proceed to the enrichment stage.

The biomarker defined cohorts may accrue at different rates related to genomic prevalence. At each stop/go decision point (end of enrichment stage 1 in a particular cohort) overall progress of all the ongoing enrichment cohorts will be reviewed by the IDMC/TSC. They will be asked to advise on the value of continued accrual to the cohorts particularly in light of slow recruitment.

03

Conditions studied

  • Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Immune checkpoint inhibitor
  • Pembrolizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, aged 18 years or older.
  2. confirmed castrate resistant adenocarcinoma of the prostate. If the patient does not have a prior histological diagnosis then the planned baseline fresh may be used for both the purpose of confirming the histological diagnosis prior to trial entry and for subsequent biomarker analysis. All patients must be willing to have fresh biopsies to obtain tumour tissue for biomarker analysis.
  3. Identified high mutational load (defined as 11 or more mutations per targeted panel - see Section 5.5 below) on next generation sequencing and/or a DNA repair defect that can increase mutation load including MMR deficiency and/or high MSI by next generation sequencing.
  4. Patients with no and only widespread bone disease must have a CTC count >5.
  5. Willing and able to comply with the follow-up schedule and the requirements of the biomarker studies including the paired fresh tumour biopsies.
  6. Written .
  7. Prior treatment with at least one of the approved treatments for mCRPC (i.e. Abiraterone, Enzalutamide, Docetaxel, Cabazitaxel, Radium 223).
  8. At least 28-days washout at trial entry since the completion of prior therapy, including major surgery, chemotherapy and other agents. For hormonal treatment and radiotherapy refer to the guidelines below:

    • At least 28-days since the completion of prior flutamide treatment. Patients whose PSA did not decline in response to antiandrogens given as a or later intervention will only require a 14-day prior to Cycle 1, Day 1.
    • At least 42-days since the completion of prior bicalutamide (Casodex) and nilutamide (Nilandron) treatment. Patients whose PSA did not decline for at least 3-months in response to antiandrogens given as second line or later intervention will require only a 14-day washout period prior to Cycle 1 Day 1.
    • At least 14-days from any radiotherapy with the exception of a single fraction of radiotherapy for the purposes of palliation (confined to one field) is permitted.
  9. Documented prostate cancer progression as assessed by the investigator with one of the following:

    • PSA progression defined by a minimum of three rising PSA levels with an interval of ≥ 1-week between each determination. The PSA value at the Screening visit should be ≥ 2 µg/L (2 ng/ml) if there is no measurable disease; patients on systemic for control of symptoms must have documented PSA progression by PCWG3 while on the same dose of systemic glucocorticoids prior to commencing Cycle1 Day1 of treatment.
    • Radiographic progression of soft tissue disease by criteria or of bone metastases by PCWG3 criteria with two or more confirmed new bone lesions on a bone scan/wb-MRI with or without PSA progression.
  10. Surgically or medically castrated, with testosterone levels of \<50 ng/dL (\<2.0 nM). If the patient is being treated with LHRH agonists (patient who have not undergone orchiectomy), this therapy must have been initiated at least 4 weeks prior to Cycle 1 Day 1 and must be continued throughout the study.
  11. (ECOG) Performance Status of 0-2.
  12. Albumin ≥25 g/L.
  13. Patient and the patient's partner of who are sexually active, must agree to use adequate methods of during the course of the study and for 120 days after the last dose of study drug (see appendix A3 for accepted methods of contraception).
  14. corrected for heart rate according to Fridericia's formula (QTcF) \<470 msec or \<480 msec with bundle branch block.
  15. Patients with primary hypothyroidism can be considered eligible if thyroid stimulating hormone (TSH) at the screening visit is within normal range while patient is under hormonal treatment.
  16. Subjects must have adequate bone marrow, hepatic and renal function documented within 7-days of trial entry defined as:

(Hb) ≥ 9.0 g/dL (ANC) ≥ 1.5 x 10\^9/L count ≥ 100 x 10\^9/L (INR) ≤ 1.5x (ULN) Or: Prothrombin time ≤ 1.5x upper limit of normal (ULN) Serum (for patients with total bilirubin >1.5x ULN) Or: Direct bilirubin ≤ 1.5x ULN ≤1.5x ULN (ALT) and aspartate aminotransferase (AST) ≤ 2.5x ULN (for patients with liver metastases ≤ 5x ULN is permissible) Serum creatinine ≤1.5 x ULN Or: Calculated >40mL/min for patients with creatinine levels above institutional normal. For estimation, the Cockcroft and Gault equation should be used: creatinine clearance = (((140 - age) x mass (kg)) x 1.23) / serum creatinine (µ mol⁄L)

Exclusion criteria

Exclusion Criteria:

    1. Patients with a history of prior treatment with , anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-0, or anti-CTLA-4 antibodies.

      1. Patients who have received any of the following concomitant therapies: IL-2, interferon or other non-study immunotherapy regimens; agents; other therapies; or chronic use of systemic (used in the management of cancer or non-cancer-related illnesses) within 1 week prior to first dose. A dose of 10mg of prednisolone or equivalent will be allowed if clinically indicated.
      1. Patients who have received any non-oncology vaccine therapy used for prevention of infectious diseases including seasonal vaccinations for up to 28-days prior to the expected start or after any dose of pembrolizumab. Examples include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, seasonal flu, H1N1 flu, rabies, BCG, and typhoid vaccine.
      1. Patients receiving growth factors including, but not limited to, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin, within 14-days of study drug administration. Use of such agents while on study is also prohibited. Prior use of growth factors should be documented in the patient's medical history.
      1. Uncontrolled intercurrent cardiovascular disease as symptomatic congestive heart failure ( Class III or IV heart disease), unstable angina pectoris, cardiac arrhythmia, poorly controlled hypertension (defined as systolic blood pressure of ≥150mmHg or diastolic blood pressure of >100 mmHg based on a mean of three measurements at approximately 2-minute intervals).
      1. Any psychiatric illness/social situations that would limit compliance with study requirements.
      1. Any acute toxicity due to prior chemotherapy and / or radiotherapy that has not resolved to a v4 grade ≤1 with the exception of chemotherapy induced alopecia and grade 2 peripheral neuropathy.
      1. Prior diagnosed within the previous 2-years with a >30% probability of recurrence within 12-months, with the exception of non-melanoma skin cancer, and in-situ or non-muscle invasive bladder cancer.
      1. Patients with myelodysplastic syndrome or acute myeloid leukaemia. 10. Patients with known active central nervous system (CNS) and/or carcinomatous meningitis. Subjects with previously treated may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
      1. Patients with symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable and asymptomatic.
      1. Any chronic respiratory disease. 13. Any immunological disorder requiring treatment with immunosuppressive treatments:
      • High dose of steroids (low dose of steroids as 10mg of prednisolone or equivalent are allowed if the patient is not able to discontinue this treatment; patient needs to be on a stable dose for at least 4-weeks before the enrolment);
      • Cytotoxic agents (such as alkylating agents or antimetabolites);
      • Antibodies (polyclonal antibodies; monoclonal antibodies different from pembrolizumab);
      • Drugs acting on immunophilins (cyclosporin, tacrolimus, sirolimus);
      • Other drugs (interferons, TNF binding proteins, mycophenolate). 14. History of any disease: patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); CNS or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis, multiple sclerosis). Patients with controlled Graves' disease will be allowed.

        1. Known history of (HIV) (HIV 1/2 antibodies). 16. Known active (e.g., HBsAg reactive) or (e.g., HCV RNA [qualitative] is detected).
        1. History of congenital function defect (e.g., Bernard-Soulier syndrome, Chediak-Higashi syndrome, Glanzmann thrombasthenia, storage pool defect).
        1. Patients with history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
        1. Initiating bisphosphonate therapy or adjusting bisphosphonate dose/regimen within 30 days prior to Cycle 1 Day 1. Patients on a stable bisphosphonate regimen are eligible and may continue.
        1. Presence of a condition or situation, which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Pembrolizumab

    Pembrolizumab will be given at a dose of 200mg IV every 3 weeks for a maximum of two years

    Drug: Pembrolizumab

Interventions

  • Pembrolizumab 200mg given as a 30 minute intravenous (IV) infusion, on day 1 of each 3 week cycle. Patients may continue with pembrolizumab treatment as long as they remain free from intolerable toxicity for a maximum of two years, if in the Investigator's opinion they are receiving clinical benefit, and/or they do not meet any discontinuation criteria.

    Also known as: Keytruda; MK-3475

06

What researchers measure

Primary outcomes

  1. To evaluate tumour response

    Responses will be defined on the basis of the following outcomes; if any of these occur patients will be considered to have responded: * Objective response by iRECIST 1.1;or * CTC count conversion from \>5 to \<5 * PSA decline of ≥50%. Responses will need confirmation by a second consecutive value obtained four or more weeks after the first value indicated a response. Evaluable patients with no confirmed response as defined above will be classified as non-responders. Response will be evaluated 6 months post-trial entry. The last value of PSA, CTC count, CT scan/bone scan/WB-MRI on or up to 28 days before the date of first study treatment will be used as the baseline value for this assessment.

    Time frame: 6 months post trial entry

Secondary outcomes

  1. Radiological progression-free survival (rPFS)

    rPFS will be measured from the date of trial entry to the first occurrence of radiological progression or death from any cause. If no event exists then rPFS will be censored at the last scheduled disease assessment on study.

    Time frame: From date of randomisation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  2. Time to radiological progression

    Death from prostate cancer or any other cause without prior radiological evidence of progression will not count as an event. If no event exists, then time to radiological progression will be censored at the last scheduled disease assessment on study or date of disease whichever occurs earlier.

    Time frame: From date of randomisation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  3. Progression free survival

    If no event exists, then PFS will be censored at the last scheduled disease assessment on study

    Time frame: From date of randomisation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

  4. Time to PSA progression

    PSA progression is defined according to the PCWG3 guidelines and is the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir (baseline if no decline) is documented. This must be confirmed by a second consecutive value obtained 4 or more weeks later.

    Time frame: From date of randomisation until the date of first documented PSA progression or date of death from any cause, whichever came first, assessed up to 100 months

  5. Duration of PSA response

    calculated from the time the PSA value first declines by at least 50% of the cycle 1 day 1 (baseline) value (must be confirmed by a second value) until the time there is an increase of 25% of PSA nadir, provided the absolute increase is at least 2 ng/mL. The increase must be confirmed by a second consecutive measurement that is at least 25% above the nadir. If the PSA never shows a 25% increase over the nadir value, then the patient will be assessed at the last PSA measurement. PSA objective response rate (PSA-ORR) is calculated as the proportion of evaluable patients who achieve a PSA response.

    Time frame: From date of first decline by at least 50% until the time time there is an increase of 25% of PSA nadir or date of death from any cause, whichever came first, assessed up to 100 months

  6. Overall survival

    Survival time of living patients will be censored on the last date a patient is known to be alive or lost to follow-up.

    Time frame: From date of randomisation until the date of death from any cause, assessed up to 100 months

  7. Safety and tolerability defined by CTC-AE, V 4.0 criteria.

    Adverse events will be summarised by grade according to the worst grade experienced. In addition, the most frequently observed AEs will be summarised.

    Time frame: From date of randomisation until the end of treatment or date of death from any cause, whichever came first, assessed up to 36 months

Other outcomes

  1. Exploratory: • Molecular endpoints from both diagnostic archival FFPE tumour tissue (when available) and fresh mCRPC tumour tissue

    PD-1, PDL-1 and PDL-2 expression

    Time frame: From date of randomisation until the end of trial or date of death from any cause, whichever came first, assessed up to 100 months

  2. Exploratory: • Molecular endpoints from both diagnostic archival FFPE tumour tissue (when available) and fresh mCRPC tumour tissue

    T-Reg infiltration (CD4+ CD25+ FoxP3+)

    Time frame: From date of randomisation until the end of trial or date of death from any cause, whichever came first, assessed up to 100 months

  3. Exploratory: • Molecular endpoints from both diagnostic archival FFPE tumour tissue (when available) and fresh mCRPC tumour tissue

    CD3, CD8, lymphocyte infiltration

    Time frame: From date of randomisation until the end of trial or date of death from any cause, whichever came first, assessed up to 100 months

  4. Exploratory: • Molecular endpoints from both diagnostic archival FFPE tumour tissue (when available) and fresh mCRPC tumour tissue

    Presence of mismatch repair defect as determined by immunohistochemistry or microsatellite instability (MSI).

    Time frame: From date of randomisation until the end of trial or date of death from any cause, whichever came first, assessed up to 100 months

  5. Exploratory: • Molecular endpoints from both diagnostic archival FFPE tumour tissue (when available) and fresh mCRPC tumour tissue

    Mutational load (number of mutations per MB of DNA sequenced)

    Time frame: From date of randomisation until the end of trial or date of death from any cause, whichever came first, assessed up to 100 months

  6. Exploratory: next generation sequencing data

    NGS data from tumour DNA and RNA including analyses of neoepitopes by targeted panel NGS and exome/transcriptome analyses when feasible.

    Time frame: From date of randomisation until the end of trial or date of death from any cause, whichever came first, assessed up to 100 months

  7. Exploratory: Immunophenotyping endpoint

    WBC immunotyping

    Time frame: From date of randomisation until the end of trial or date of death from any cause, whichever came first, assessed up to 100 months

  8. Exploratory:Whole blood mRNA expression profiling

    Whole blood mRNA expression profiling

    Time frame: From date of randomisation until the end of trial or date of death from any cause, whichever came first, assessed up to 100 months

  9. Exploratory: Immune cell genomics including T-cell receptor sequencing

    Immune cell genomics including T-cell receptor sequencing

    Time frame: From date of randomisation until the end of trial or date of death from any cause, whichever came first, assessed up to 100 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2018 (actual). Primary completion is estimated for Sep 2023, 57 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 57 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2018
First posted
Apr 24, 2018
StartActual
Nov 27, 2018
Primary completionEst.
Sep 1, 2023
CompletionEst.
Sep 1, 2025
Last update
Jul 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03506997
Responsible party
Sponsor
First posted
Apr 24, 2018
Start date
Nov 27, 2018
Primary completion
Sep 1, 2023 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Jul 22, 2020

Study contacts

Stephanie M Burnett, BSc
Contact
perseus-icrctsu@icr.ac.uk
02087224261 ext. 4261
Ajit Sarvadikar
Contact
perseus-icrctsu@icr.ac.uk
020 8722 4329 ext. 4329
Johann de Bono
principal investigator · The Institute of Cancer Research/The Royal Marsden NHSFT

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion